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ABSTRACT: Potent and selective chemical probes are valuable tools for discovery of novel treatments for human
diseases. NF-kB-inducing kinase (NIK) is a key trigger in the development of liver injury and fibrosis. Whether
inhibition ofNIKactivityby chemical probes ameliorates liver inflammation and injury is largely unknown. In this
study, a small-molecule inhibitor of NIK, B022, was found to be a potent and selective chemical probe for liver
inflammation and injury. B022 inhibited the NIK signaling pathway, including NIK-induced p100-to-p52 pro-
cessing and inflammatory gene expression, both in vitro and in vivo. Furthermore, in vivo administration of B022
protected against not only NIK but also CCl4-induced liver inflammation and injury. Our data suggest that in-
hibition of NIK is a novel strategy for treatment of liver inflammation, oxidative stress, and injury.—Ren, X., Li, X.,
Jia, L., Chen, D., Hou, H., Rui, L., Zhao, Y., Chen, Z. A small-molecule inhibitor of NF-kB-inducing kinase (NIK)
protects liver from toxin-induced inflammation, oxidative stress, and injury. FASEB J. 31, 711–718 (2017).
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Liver injury represents a growing major health concern
worldwide. Specifically, toxin-induced liver injury has
dramatically increased in both developed and developing
countries. Toxins [e.g., drugs, herbals, and carbon tetra-
chloride (CCl4)] cause hepatocyte damage by increasing
permeability of cellular membranes (1), concentrations of
highly reactive free radicals (2), and expression of proin-
flammatory cytokines (e.g., TNF-a and IL-6) (3, 4), even-
tually resulting in severe apoptosis and necrosis (5, 6). The
detailed molecular mechanisms of toxin-induced liver in-
jury are not fully understood. It has not been completely
demonstrated whether selective chemical probes can be
valuable tools for the treatment of liver injury.
Recently, the noncanonical NF-kB signaling pathway
has been shown to play an important role in the devel-
opment of liver injury and fibrosis (7, 8). The critical event
in this signaling pathway is the accumulation of NF-kB-
inducing kinase (NIK), which phosphorylates IKKa and
NF-kB2, leading to p100-to-p52 processing (9–11). p52 is
the mature form of NF-kB2, which triggers the expression
of inflammatorygenes (9, 10, 12). Inpatientswithcirrhosis,
the levels of bothNIKmRNA and p52 protein are signifi-
cantly increased. In a CCl4- or alcohol-induced liver injury
mouse model,NIKmRNA and p52 protein levels are also
abnormally augmented. Liver-specific overexpression of
NIK induces hepatocytes to secrete proinflammatory cy-
tokines that cause liver inflammation and destruction,
leading to death in mice (7). Overall, NIK activation is
prone to cause liver inflammation and injury.
Given the strong association between NIK activation
and liver injury, inhibition ofNIK or theNF-kB2 signaling
pathway represents attractive therapeutic strategies for
the treatment of liver inflammation and injury. A small
molecule, B022, has been reported to be a potent inhibitor
of NIK activity, with Ki = 4.2 nM in an ATP-consumption
assay (13). A derivative of B022, AM-0216 in the low mi-
cromolar range has exhibitedNIK-dependent cytotoxicity
inmyelomacells (14).However,whether inhibitionofNIK
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by B022 ameliorates liver inflammation and injury is
largely unknown.
In this study, B022 suppressed NIK-induced liver in-
flammation and injury. It decreased NIK-induced p100-to-
p52 processing and inflammatory gene expression in
hepatocytes. Intravenous administration of B022 in mice
ameliorated both NIK- and CCl4-induced liver inflamma-
tion and injury. These observations indicate that inhibition
ofNIKactivityby smallmolecules couldbe anovel strategy
for the treatment of liver inflammation and injury.
MATERIALS AND METHODS
Animal experiments
Animal experiments were performed in strict accordance with
the Guide for the Care and Use of Laboratory Animals (National
Institutes ofHealth, Bethesda,MD,USA), andwere approved by
the Institutional Animal Care and Use Committee or Animal
Experimental EthicsCommitteeofNortheastNormalUniversity.
STOP-NIK mice (C57BL/6 background) are described in Shen
et al. (7) and Jiang et al. (8). STOP-NIK male mice (8 wk) were
infected with Ad-cre (2 3 1011 viral particles per mouse) via tail
vein injection and then were injected with B022 (30 mg/kg
bodyweight) or an equal volume of vehicle via tail vein twice a
day for 10 d. For the CCl4-induced liver injury mouse model,
wild-type (WT) C57BL/6 WT mice were intraperitoneally in-
jected with CCl4 (2.5 ml/kg bodyweight, 10% in olive oil) and
then injected with B022 (25 mg/kg bodyweight) or an equal
volumeofvehiclevia tail veinat 0, 3, 6, and9hafterCCl4 injection.
The mice were euthanized at 12 h after CCl4 injection. Blood
samples were collected from the retro-orbital sinus. Blood glu-
cose levels were determined with glucometers (Beijing Yicheng
Bioelectronics Technology Co., Beijing, China). The plasma ala-
nineaminotransferase (ALT) activity levelwasmeasuredwithan
ALT reagent set.
Chemical synthesis of the NIK inhibitor B022
The synthesis of B022 was performed based on a reported pro-
cedure, with modifications (15). The synthetic route and charac-
terization data are provided in the Supplemental Data.
Cell culture and adenoviral infection
HEK293andHepa1cellsweregrownat37°C in5%CO2 inDMEM
supplemented with 100 U/ml penicillin, 100 U/ml streptomycin,
and 10% fetal bovine serum. Primary hepatocytes were isolated
from C57BL/6 WT mice (16, 17). Hepa1 cells and primary hepa-
tocytes were then infected with adenoviruses (8, 18).
Treatment of RAW cells with hepatocyte-
conditioned medium
Primary hepatocytes were infectedwith b-galactosidase (b-Gal),
infected with NIK adenovirus, or infected with NIK adenovirus
and treated with B022 (10 mM) for 18 h. b-Gal and NIK
adenovirus–infected groups were then grown in fresh growth
medium. The groups of NIK adenovirus-infected cells treated
with B022 (10 mM) were then cultured in fresh growth medium
containing B022 (10 mM). Hepatocyte-conditioned mediumwas
collected 24 h later (7). RAW cells were treated with 50%
hepatocyte-conditioned medium for 12 h. Gene expression was
measured by quantitative PCR (qPCR).
Transient transfection and luciferase assays
HEK293 cells were divided equally in a 24-well plate and cul-
tured for 20 h, and then cotransfected with NF-kB luciferase re-
porter plasmids with NIK or an empty expression vector via
polyethylenimine (Sigma-Aldrich, St. Louis, MO, USA). Twelve
hours later, theHEK293 cellswere incubatedwithdifferentdoses
of B022 (0, 0.5, or 5 mM) for another 36 h. The cells were lysed in
reporter lysis buffer (Promega, Madison, WI, USA) 48 h after
transfection, and luciferase activity was measured and normal-
ized to b-Gal activity (19).
Immunoblot analysis
Immunoblot analysis has been described in several publications
(17, 20, 21). In brief, cells or tissues were homogenized in an
L-RIPA lysis buffer [50 mM Tris (pH 7.5), 1% Nonidet P-40,
150 mM NaCl, 2 mM EGTA, 1 mM Na3 VO4, 100 mM NaF,
10 mM Na4P2O7, and 1 mM PMSF]. Protein was separated by
SDS-PAGE, immunoblotted with the indicated antibodies, and
visualizedbyECL.Antibodydilution ratioswere as follows: Flag
(F1804, 1:4000; Sigma-Aldrich), NF-kB2 (4882, 1:4000; Cell Sig-
naling Technology, Danvers, MA, USA), tubulin (sc5286, 1:5000;
Santa Cruz Biotechnology, Dallas TX, USA), and lamin B1
(12987-1-AP, 1:5000; Proteintech, Chicago, IL, USA).
Reactive oxygen species assays
Reactive oxygen species (ROS) assays have been described (7). In
brief, liver samples were homogenized in L-RIPA buffer. Liver
TABLE 1. Primers for qPCR
Primer, 59–39
Genes Forward Reverse
TNFa CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
IL6 AGCCAGAGTCCTTCAGA GGTCCTTAGCCACTCCT
IL1b GCCTTGGGCCTCAAAGGAAAGAATC GGAAGACACAGATTCCATGGTGAAG
iNOS CAGGGCCACCTCTACATTTG TGCCCCATAGGAAAAGACTG
NIK TCTCTGGAGGAACAGGAACAA GCCATTGAGAGACTGGATCTG
36B4 AAGCGCGTCCTGGCATTGTCT CCGCAGGGGCAGCAGTGGT
CCL2 ACTGAAGCCAGCTCTCTCTTCCTC TTCCTTCTTGGGGTCAGCACAGAC
CCL5 CCACTTCTTCTCTGGGTTGG GTGCCCACGTCAAGGAGTAT
CXCL5 TGCATTCCGCTTAGCTTTCT CAGAAGGAGGTCTGTCTGGA
p100 CCACCAGCCAGCTTGTAA TGCTGCTAAATGCTGCTCA
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extracts were incubated with dichlorofluorescein diacetate fluo-
rescent (final concentration, 5 mM) probes (D6883; Sigma-
Aldrich) at 37°C for 1 h. Fluorescence was measured with an
Infinite 200 Pro microplate reader (Tecan, Ma¨nnedorf, Switzer-
land) and normalized to tissue weight.
Real-time qPCR
Total RNAs were extracted using TriPure Isolation Reagent
(Roche Diagnostics, Mannheim, Germany), and the first-strand
cDNAs were synthesized with random primers and M-MLV
reverse transcriptase (Promega) (16). RNA abundance was
measured with qPCR SYBRMix and a LightCycler 480 real-time
PCR system (both from Roche Diagnostics). The expression of
individual genes was normalized to the expression of 36B4, a
housekeeping gene. Primers for real-time qPCR were listed in
Table 1.
Statistical analysis
Data are presented as means 6 SE. Differences between groups
were analyzed by Student’s t tests, with P, 0.05 indicating sta-
tistical significance.
RESULTS
B022 suppresses NIK/NF-kB2 signaling
TodeterminewhetherB022 inhibitsNIK-inducedp100-to-
p52 processing in hepatocytes, Hepa1 cells were infected
with p100 andNIK adenoviruses and treatedwith B022 at
different doses. NIK overexpression dramatically pro-
moted p100-to-p52 processing, as judged by immunoblot
assay. Furthermore, B022 suppressed NIK-induced p52
formation in a dose-dependent manner (Fig. 1A).
We then measured NF-kB2 activity by using an NF-kB
luciferase reporter assay. The NF-kB luciferase reporter
plasmid was transiently transfected into HEK293 cells,
togetherwith anNIKexpressionplasmid. These cellswere
subsequently treated with B022 at different doses, and
luciferase activity was measured 48 h after transfection.
NF-kB luciferase reporters are expected to be activated by
endogenous NF-kB2. NIK markedly increased NF-kB lu-
ciferase reporter activity, which was suppressed by B022
dose dependently (Fig. 1B). In the absence of NIK, B022
alonedid not alter basalNF-kB luciferase reporter activity.
Taken together, these data suggest that B022 suppresses
NIK-induced activation of endogenous NF-kB2.
B022 blocks NIK-induced inflammatory gene
expression in hepatocytes
To determine whether B022 inhibits NIK-induced ex-
pression of inflammatory genes in hepatocytes, Hepa1
cells or primary hepatocytes were infected with NIK
adenoviruses, and then treated with B022 at different
doses. Gene expression was measured by qPCR. Com-
pared with b-Gal, NIK largely triggered the expression
of liver chemokines (e.g., CCL2, CCL5, and CXCL5),
proinflammatory cytokines (TNF-a and IL-6), and iNOS
(Fig. 2; Supplemental Fig. S1). In addition, B022 dose-
dependently blocked NIK-induced expression of chemo-
kines, cytokines, and iNOS in these cells.
To further determine the time course of the inhibitory
effect of B022 on gene expression in hepatocytes, Hepa1
cells were infectedwith NIK adenovirus, and then treated
with B022 (5 mM) for different durations (0, 1, 2, 4, or 8 h).
Treatment with B022 for 1 h was sufficient to inhibit NIK-
inducedTNF-a expression (Fig. 3A). B022 treatment for 8h
completely blocked NIK-induced expression of TNF-a,
IL-6, iNOS, CCL2, and CXCL5 (Fig.3A–D, F). NIK-
induced expression of CCL5 was also decreased after
B022 treatment for 8 h (Fig. 3E). These data indicate that
B022 acts quickly to inhibit NIK activity in Hepa1 cells.
Figure 1. B022 suppresses NIK-stimulated activation of the
noncanonical NF-kB2 signaling pathway. A) Hepa1 cells were
infected with p100 and Flag-tagged NIK adenovirus in the
presence of B022 at different doses (0, 0.5, or 5 mM). Cell
extracts were prepared 12 h after B022 treatment and
immunoblotted with antibodies to NF-kB2, Flag, or tubulin.
B) NF-kB luciferase reporter and NIK plasmids were cotrans-
fected into HEK293 cells. Twelve hours after transfection,
HEK293 cells were treated with B022 at different doses (0, 0.5,
or 5 mM) for another 36 h. Luciferase activity was then
measured and normalized to b-Gal activity (n = 4). **P , 0.01.
Au, arbitrary unit.
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B022 inhibits NIK-triggered liver
inflammation and injury
To testwhetherB022 suppressesNIKaction inanimals,we
employed STOP-NIKmice, in which a STOP-NIK cassette
is knocked into theRosa26 locus. Cre-mediated deletion of
the STOP sequences activates NIK overexpression (7, 8).
We injected purified cre adenoviruses, which express Cre
under the control of the CMV promoter, to generate liver-
specificNIK transgenicmice (7, 8). LiverNIKmRNAlevels
were much higher in the cre group than in the control
group (Fig. 4A). p100mRNA levels were also significantly
increased (Fig. 4B), and p52 NF-kB2 protein levels were
dramatically increased (17-fold) in the cregroup than in the
control group (Fig. 4C). Consistentwith the in vitro assays,
intravenous administration of B022 in the cre group de-
creased the levels of the mature form of p52 NF-kB2 by
;62% (Fig. 4C) without affecting NIK and p100 mRNA
levels (Fig. 4A,B) in the liver, presumably because of direct
inhibition of NIK activity.
It has been reported that hepatocyte-specific activation
of the NIK transgene results in liver inflammation and
injury, leading to death in mice (7, 8). To determine
whether B022 attenuates the detrimental effect of NIK in
the liver, STOP-NIKmice were infected with cre adenovi-
rus via tail vein injection, and then B022 or vehicle was
injected via tail vein twice a day for 10 d. Liver-specific
activation of theNIK transgene causeddeath of STOP-NIK
mice within 10 d after infection with cre adenovirus, and
intravenous administration of B022 completely rescued
them from NIK-induced death (Fig. 4D). These data
demonstrate that B022 completely prevents the lethal
effect of abnormally high levels of hepatic NIK in mice.
Liver-specific activation of NIK causes liver injury, as
revealedbydecreasedbloodglucose levels, increasedblood
ALT activity, liver weight, liver inflammation, and liver
oxidative stress in STOP-NIK mice infected with cre ade-
noviruses (7). Intravenous administration of B022 largely
prevented these harmful effects of aberrant hepatic NIK in
STOP-NIKmice infectedwith creadenovirus, as revealedby
significantly increased blood glucose levels (Fig. 4E), de-
creased bloodALT activity (Fig. 4F), decreased liverweight
(Fig. 4G), reduced immune cell infiltration into the liver (Fig.
4H), decreased levels of reactive oxygen species (Fig. 4I),
reducedTUNEL+ cells (Fig. 4J), anddecreased expressionof
proinflammatory genes (Fig. 4K). Together, these results
demonstrate that B022 inhibits the majority of the deterio-
rating effects of aberrant activation of hepatic NIK.
Hepatocyte-specific overexpression of NIK has been
shown to trigger liver injury and fibrosis,which is associated
with macrophages (7). We determined whether B022 af-
fects the crosstalk between hepatocytes andmacrophages.
Primary hepatocytes were infected with b-Gal, NIK adeno-
virus, or NIK adenovirus plus B022, and the hepatocyte-
conditioned media were collected. RAW cells were treated
with each conditioned medium. NIK adenovirus plus treat-
ment with B022 hepatocyte-conditioned medium signifi-
cantly suppressed theexpressionof iNOSand IL-1b inRAW
cells (Supplemental Fig. S2), indicating that B022 may also
prevent macrophage-induced inflammation in liver injury.
B022 ameliorates CCl4-induced acute liver
inflammation and injury
To further determine whether B022 ameliorates CCl4-in-
duced liver inflammation and injury in mice, WT mice
were intraperitoneally injected with CCl4, and B022 or
vehicle was injected via the tail vein every 3 h. CCl4 in-
creases the NIK mRNA and p52 NF-kB2 levels (7). In
agreement, liverNIK and p100mRNAsweremuch higher
in the CCl4-injectedmice than in the control mice (Fig. 5A,
B). p52 NF-kB2 protein levels increased by 2.1-fold in the
CCl4-injected mice compared with those in the control
mice (Fig. 5C), whereas intravenous administration of
Figure 2. B022 dose-dependently blocks NIK-stimulated
expression of inﬂammatory factors. Hepa1 cells were
infected with NIK adenovirus in the presence of B022 at
different doses (0, 0.5, or 5 mM) for 12 h. The expression of
TNF-a (A), IL-6 (B), iNOS (C ), CCL2 (D), CCL5 (E ), and
CXCL5 (F ) was measured by qPCR (n = 6). **P , 0.01.
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B022 inCCl4-injectedmicedecreased these levels by;73%
in the liver without affecting NIK and p100mRNA levels
(Fig. 5A–5C). These results further confirm the specificity
of NIK inhibition by B022. Moreover, B022 injection sig-
nificantly decreased bloodALT activity (Fig. 5D), immune
cell infiltration into the liver (Fig. 5E), levels of ROS (Fig.
5F), and the number of TUNEL+ cells (Fig. 5G). CCl4 in-
jection significantly increased expression of proin-
flammatory genes (Fig. 5H–M), while treatment with
B022 also dramatically decreased expression of proin-
flammatory genes (Fig. 5H–K,M). Together, these results
demonstrate that B022 ameliorates CCl4-induced liver
inflammation and injury, indicating that inhibition of
NIK activity by a small molecule could be a novel strat-
egy for treatment of liver inflammation and injury.
DISCUSSION
Liver injury and chronic inflammation are two major
causes of liver fibrosis and cirrhosis that lead to mortality
and morbidity. JNK, IKK/NF-kB, and TGF-b signaling
pathways have been shown to promote liver injury, in-
flammation, and fibrosis (22). Inhibition of JNK by its in-
hibitor SP600125 ameliorates both CCl4 and bile duct
ligation-induced liver fibrosis (23). Pirfenidone, an in-
hibitor ofTGF-bproduction,hasbeen evaluated ina small
study inHCV-related fibrosis (24) and has been shown to
improve long-term liver inflammation and fibrosis (24,
25). IFN-g, an endogenous antagonist of TGF-b, has been
shown to reduce the expression of type I and IV collagen,
fibronectin, and SMA (26). IFN-b1b is currently in a phase
II study in patients with liver fibrosis and cirrhosis
(NCT00043303; https://clinicaltrials.gov) (25).
Recently, NIK/p52NF-kB2 has been shown to be a key
trigger for liver injury (7, 8). Hepatic NIK is aberrantly
activated in multiple liver diseases, including alcoholic
liver disease, drug-induced liver disease, and primary
biliary cirrhosis (7). In mice, hepatocyte-specific over-
expression of NIK is sufficient to cause severe liver in-
flammation and injury, leading to death within a few
weeks (7). Several small molecules have been reported to
be inhibitors ofNIK activity in anATP consumption assay
(13). In this study, we tested whether inhibition of NIK
activity by one of these small molecules (B022) could
ameliorate liver inflammation and injury.
In our study, B022 directly inhibited NIK activity in
Hepa1 cells and primary hepatocytes. It inhibited NIK-
induced p100-to-p52 processing, and the expression of
inflammatory cytokines and iNOS genes. Moreover, we ob-
served in vivo that B022 completely reversed NIK-induced
hepatocyte death and largely corrected the abnormalities
caused by hepatocyte-specific overexpression of NIK (e.g.,
loss of bodyweight, hypoglycemia, liver inflammation,
liver oxidative stress, and hepatomegaly). These findings
demonstrate that B022 specifically suppresses the abnor-
mal activation of NIK, thus protecting against liver injury.
Toxins (CCl4) cause hepatocyte death by increasing
permeability of cellular membranes (1), concentrations of
highly reactive free radicals (2), and expression of proin-
flammatory cytokines (TNF-a and IL-6) (3, 4). It has been
shown that NIK/p52 NF-kB2 is strongly associated with
toxin (CCl4)-induced liver injury (7). In our study, the ex-
pression of NIK/p52 NF-kB2 was dramatically increased
in CCl4-induced liver injury. Inhibition of NIK by B022
completely blocked CCl4-induced nuclear p52 protein
levels in the liver. B022 injection also significantly reduced
blood ALT activity, number of TUNEL+ cells, and expres-
sion of proinflammatory genes. Moreover, B022 injection
completely reversed CCl4-induced iNOS gene expression
and ROS levels in the liver. These observations indicate
that B022 ameliorates CCl4-induced liver injury primarily
through the inhibition of p52 and ROS formation.
NIK- or CCl4-induced liver injury and fibrosis are
stronglyassociatedwithmacrophage-induced inflammation
(7). Conditioned medium from NIK-overexpressing hepa-
tocytes dramatically triggered RAW cells to express iNOS
and IL-1b, but B022 treatment significantly suppressed
Figure 3. B022 time-dependently inhibits NIK-stimulated
expression of inﬂammatory factors. Hepa1 cells were infected
with NIK adenovirus in the presence of B022 (5 mM) for
different times (0, 1, 2, 4, or 8 h). The expression of TNF-a
(A), IL-6 (B), iNOS (C), CCL2 (D), CCL5 (E), and CXCL5 (F)
was measured by qPCR (n = 4). *P , 0.05; **P , 0.01.
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those effects. This finding indicates that B022 may also pre-
vent macrophage-induced inflammation in liver injury. The
therapeutic role of B022 in macrophage-induced inflamma-
tion and related diseases should be further examined.
It has been reported that the in vivo pharmacokinetic
properties of this class of NIK inhibitor are not optimal. In
linewithanother report (14),multiple tandem,highdosesof
B022 are necessary to achieve in vivo inhibition of NIK- or
Figure 4. B022 suppresses NIK-triggered liver inﬂammation and injury. STOP-NIKmale mice (8 wk) were infected with Ad-cre (23
1011 viral particles per mouse) and ad-GFP via tail vein injection. Cre-injected mice were then injected with B022 (30 mg/kg
bodyweight) or an equal volume of vehicle via the tail vein twice a day for 10 d. A, B) Liver NIK (A) and p100 (B) mRNA levels
were measured by qPCR and normalized to 36B4 levels. C) Liver extracts were prepared and immunoblotted with antibodies to
NF-kB2 or tubulin. D–J ) Survival curves (D), blood glucose levels (E), blood ALT activity (F), liver weight (% bodyweight) (G),
H&E staining (H), liver reactive oxygen species (ROS) levels (I), and TUNEL staining of frozen liver sections (J ). K) Liver
mRNA abundance was measured by qPCR and normalized to 36B4 levels. n = 3–9. *P , 0.05; **P , 0.01.
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Figure 5. B022 ameliorates CCl4-induced acute liver injury. For a CCl4-induced liver injury mouse model, WT C57BL/6 mice were
intraperitoneally injected with CCl4 (2.5 ml/kg bodyweight, 10% in olive oil) and then with B022 (25 mg/kg bodyweight) or an
equal volume of vehicle, via the tail vein at 0, 3, 6, or 9 h after CCl4 injection. The mice were euthanized at 12 h after CCl4
injection. A, B) Liver NIK (A) and P100 (B) mRNA levels were measured by qPCR and normalized to 36B4 levels. C) Liver
nucleus extracts were prepared and immunoblotted with antibodies to NF-kB2 or lamin B1. D–G) Blood ALT activity levels (D),
H&E staining (E), liver reactive oxygen species (ROS) levels (F), and TUNEL staining of frozen liver sections (G) were observed
and recorded. H–M) The expression of TNF-a (H), IL-6 (I), iNOS (J ), CCL2 (K), CCL5 (L), and CXCL5 (M) was measured by
qPCR and normalized to 36B4 levels. n = 3–9. *P , 0.05; **P , 0.01.
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CCl4-induced liver injury and inflammation (rather than 1
or 2 doses). Therefore, further modifications to B022 are
needed toachievebetter invivopharmacokineticproperties.
In summary, in our study, B022, an inhibitor of NIK,
amelioratedNIK-induced liver inflammation, both in vitro
and in vivo. B022 protected mice from NIK-induced liver
failure and subsequent death. Moreover, it reduced CCl4-
induced liver inflammation and injury in mice. Our data
suggest that further efforts toward the development of
B022 analogs could yield therapeutic drugs for the treat-
ment of liver inflammation, oxidative stress, and injury.
ACKNOWLEDGMENTS
The authors thank laboratory members Wangshu Qin, Sha
Li, Xue Dong, Xiaoyue Chen, and Jiana Liu (Northeast
Normal University), for helpful discussions and Shu-Sin Chng
(National University of Singapore) for proofreading the
manuscript. This study was supported by Changbai Mountain
Scholars Program of The People’s Government of Jilin
Province Grant 2013046, Jilin Science and Technology Devel-
opment Program Grant 20160101204JC, Jilin Talent Develop-
ment Foundation Grant 111860000, Fok Ying Tong Education
Foundation Grant 151022 , National Natural Science Founda-
tion of China Grants 31500957 and 31671225, and startup
funds from Northeast Normal University 120401204 (all to
Z.C.), and a Shanghai Institute of Materia Medica startup
grant and Young Overseas High-Level Talents Introduction
Plan from the Chinese government (to Y.Z.). The authors
declare no conﬂicts of interest.
AUTHOR CONTRIBUTIONS
Z. Chen conceived of and designed the project, analyzed
the data, and wrote the manuscript; X. Ren, X. Li., L. Jia,
and H. Hou analyzed the data; L. Rui provided STOP-NIK
mice and reagents and reviewed the manuscript; and
D. Chen and Y. Zhao synthesized B022 and reviewed and
edited the manuscript.
REFERENCES
1. Berger, M. L., Bhatt, H., Combes, B., and Estabrook, R. W. (1986)
CCl4-induced toxicity in isolated hepatocytes: the importance of di-
rect solvent injury.Hepatology 6, 36–45
2. Lee, I.-C., Kim, S.-H., Baek, H.-S., Moon, C., Kang, S.-S., Kim, S.-H.,
Kim,Y.-B., Shin, I.-S., andKim, J.-C. (2014)The involvementofNrf2 in
the protective effects of diallyl disulﬁde on carbon tetrachloride-
inducedhepaticoxidativedamageand inﬂammatoryresponse in rats.
Food Chem. Toxicol. 63, 174–185
3. Kovalovich, K., DeAngelis, R. A., Li,W., Furth, E. E., Ciliberto, G., and
Taub, R. (2000) Increased toxin-induced liver injury and ﬁbrosis in
interleukin-6-deﬁcient mice. Hepatology 31, 149–159
4. Czaja, M. J., Xu, J., and Alt, E. (1995) Prevention of carbon
tetrachloride-induced rat liver injury by soluble tumor necrosis fac-
tor receptor. Gastroenterology 108, 1849–1854
5. Slater, T. F. (1966) Necrogenic action of carbon tetrachloride in the
rat: a speculative mechanism based on activation. Nature 209, 36–40
6. Shi, J., Aisaki, K., Ikawa, Y., and Wake, K. (1998) Evidence of
hepatocyte apoptosis in rat liver after the administration of carbon
tetrachloride. Am. J. Pathol. 153, 515–525
7. Shen, H., Sheng, L., Chen, Z., Jiang, L., Su, H., Yin, L., Omary, M. B.,
and Rui, L. (2014) Mouse hepatocyte overexpression of NF-kB-
inducing kinase (NIK) triggers fatal macrophage-dependent liver
injury and ﬁbrosis. Hepatology 60, 2065–2076
8. Jiang, B., Shen, H., Chen, Z., Yin, L., Zan, L., and Rui, L. (2015)
Carboxyl terminus of HSC70-interacting protein (CHIP) down-
regulates NF-kB-inducing kinase (NIK) and suppresses NIK-induced
liver injury. J. Biol. Chem. 290, 11704–11714
9. Xiao,G., Fong,A., andSun, S.-C. (2004) Inductionof p100processing
by NF-kappaB-inducing kinase involves docking IkappaB kinase a
(IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J. Biol.
Chem. 279, 30099–30105
10. Xiao, G., Harhaj, E. W., and Sun, S. C. (2001) NF-kappaB-inducing
kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7,
401–409
11. Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Kra¨hn, G., Bonizzi, G.,
Chen, Y., Hu, Y., Fong, A., Sun, S. C., and Karin, M. (2001) Activation
by IKKalpha of a second, evolutionary conserved, NF-kappa B sig-
naling pathway. Science 293, 1495–1499
12. Sun, S.C. (2011)Non-canonicalNF-kB signaling pathway.Cell Res.21,
71–85
13. DeLeon-Boenig, G., Bowman, K. K., Feng, J. A., Crawford, T., Everett,
C., Franke, Y., Oh, A., Stanley, M., Staben, S. T., Starovasnik, M. A.,
Wallweber,H. J.,Wu, J.,Wu, L.C., Johnson, A.R., andHymowitz, S.G.
(2012) The crystal structure of the catalytic domain of the NF-kB
inducing kinase reveals a narrow but ﬂexible active site. Structure 20,
1704–1714
14. Demchenko, Y. N., Brents, L. A., Li, Z., Bergsagel, L. P., McGee, L. R.,
and Kuehl, M. W. (2014) Novel inhibitors are cytotoxic for myeloma
cells with NFkB inducing kinase-dependent activation of NFkB.
Oncotarget 5, 4554–4566
15. Chen, G., Cushing, T. D., Fisher, B., He, X., Li, K., Li, Z., Mcgee, L. R.,
Pattaropong, V., Faulder, P., Seganish, J. L., Shin, Y. Alkylnyl alcohols
as kinase inhibitors. PCT Patent Publication WO 2009159011, De-
cember 30, 2009
16. Qin,W., Li, X., Xie, L., Li, S., Liu, J., Jia, L., Dong,X., Ren, X., Xiao, J.,
Yang, C., Zhou, Y., and Chen, Z. (2016) A long non-coding RNA,
APOA4-AS, regulates APOA4 expression depending onHuR inmice.
Nucleic Acids Res. 44, 6423–6433
17. Chen, Z., Canet, M. J., Sheng, L., Jiang, L., Xiong, Y., Yin, L., and Rui,
L. (2015) Hepatocyte TRAF3 promotes insulin resistance and type 2
diabetes in mice with obesity.Mol. Metab. 4, 951–960
18. Chen,Z., Sheng, L., Shen,H., Zhao, Y.,Wang, S., Brink,R., andRui, L.
(2012) Hepatic TRAF2 regulates glucose metabolism through
enhancing glucagon responses. Diabetes 61, 566–573
19. Chen, Z., Morris, D. L., Jiang, L., Liu, Y., and Rui, L. (2014) SH2B1 in
b-cells promotes insulin expression and glucose metabolism inmice.
Mol. Endocrinol. 28, 696–705
20. Chen, Z., Shen, H., Sun, C., Yin, L., Tang, F., Zheng, P., Liu, Y., Brink,
R., and Rui, L. (2015) Myeloid cell TRAF3 promotes metabolic
inﬂammation, insulin resistance, and hepatic steatosis in obesity. Am.
J. Physiol. Endocrinol. Metab. 308, E460–E469
21. Chen, Z., Morris, D. L., Jiang, L., Liu, Y., and Rui, L. (2014) SH2B1 in
b-cells regulates glucosemetabolismby promoting b-cell survival and
islet expansion. Diabetes 63, 585–595
22. Cubero, F. J., Zhao, G., Nevzorova, Y. A., Hatting,M., AlMasaoudi,
M., Verdier, J., Peng, J., Schaefer, F. M., Hermanns, N.,
Boekschoten, M. V., Grouls, C., Gassler, N., Kiessling, F., Muller, M.,
Davis, R. J., Liedtke, C., and Trautwein, C. (2015) Haematopoietic
cell-derived Jnk1 is crucial for chronic inﬂammation and carcino-
genesis in an experimental model of liver injury. J. Hepatol. 62,
140–149
23. Kluwe, J., Pradere, J.-P., Gwak, G.-Y., Mencin, A., De Minicis, S.,
Osterreicher, C. H., Colmenero, J., Bataller, R., and Schwabe, R. F.
(2010) Modulation of hepatic ﬁbrosis by c-Jun-N-terminal kinase in-
hibition. Gastroenterology 138, 347–359
24. Armenda´riz-Borunda, J., Islas-Carbajal, M. C., Meza-Garcı´a, E.,
Rinco´n, A. R., Lucano, S., Sandoval, A. S., Salazar, A., Berumen, J.,
Alvarez, A., Covarrubias, A., Are´chiga, G., and Garcı´a, L. (2006) A
pilot study in patients with established advanced liver ﬁbrosis using
pirfenidone. Gut 55, 1663–1665
25. Fagone, P., Mangano, K., Pesce, A., Portale, T. R., Puleo, S., and
Nicoletti, F. (2016)Emerging therapeutic targets for the treatment of
hepatic ﬁbrosis. Drug Discov. Today 21, 369–375
26. Rockey, D. C., and Chung, J. J. (1994) Interferon gamma inhibits
lipocyte activation and extracellularmatrixmRNA expression during
experimental liver injury: implications for treatment of hepatic
ﬁbrosis. J. Investig. Med. 42, 660–670
Received for publication July 19, 2016.
Accepted for publication October 24, 2016.
718 Vol. 31 February 2017 REN ET AL.The FASEB Journal x www.fasebj.org
